CROWN POINT, Ind. — OYE Therapeutics Inc., a privately held biopharmaceutical company developing first-in-class intravenous caffeine-based therapies for anesthesia recovery and opioid-induced respiratory depression, has announced the successful close of its $5 million convertible note financing, positioning the company to enter clinical development.
The company is headquartered at the Purdue Technology Center of Northwest Indiana.
CEO Brett Dines said the round drew strong new investor participation and was oversubscribed to $5.6 million, reflecting sustained confidence across OYE’s investor base.
Advancing to the clinic
Proceeds from the raise will support OYE’s Phase 1 pharmacokinetic and safety study and its subsequent pivotal trials. This dataset will be leveraged across all investigational new drugs (INDs), enabling an accelerated multitrack clinical program.
Dines said closing the round marks a transformative moment for the company.
“The confidence shown by our investors underscores the strength of our science and our mission,” he said. “With this financing, we are well positioned to enter the clinic and generate meaningful clinical data.”
Looking ahead
OYE anticipates sharing top-line clinical results in 2026, a key milestone expected to expand engagement with strategic and financial partners across the health care sector.
Dines said moving into the clinical stage is a defining moment for the company and its technology.
“We look forward to demonstrating the potential of our therapy in several prospective pivotal studies to improve anesthesia recovery and address opioid-induced respiratory depression in both hospital and emergency care settings,” he said.
About OYE Therapeutics
OYE Therapeutics Inc. is a biopharmaceutical company based at the Purdue Technology Center of Northwest Indiana developing intravenous caffeine-based therapies intended to reverse general anesthesia, sedation and opioid-induced respiratory depression. Supported by public and private investment, OYE’s programs aim to address significant unmet needs in perioperative and acute care medicine.
Media Contact: Michael Hicks, Chief Operating Officer, mhicks@oyetherapeutics.com, 219-281-2369